Fenofibrate as an anti-cancer treatment: an in vitro study on glioblastoma cells at various oxygen levels and on normal astrocytes
), reducing their proliferation. Under the experimental conditions tested, namely in vitro studies, fenofibrate appeared more efficient compared with temozolomide, the standard treatment for GBM. This study demonstrated the cytotoxic and cytostatic effect of fenofibrate on GBM cells. These results indicate that fenofibrate may be a therapeutic alternative for GBM treatment.
Authors
- Sophie Corvaisier (ORCID: https://orcid.org/0000-0002-4242-6179)
- Aurélie Malzert‐Fréon (ORCID: https://orcid.org/0000-0001-6023-1861)
- Anne‐Claire Groo (ORCID: https://orcid.org/0000-0001-6068-5871)
- Samuel Valable (ORCID: https://orcid.org/0000-0003-0355-0270)
- Yasmine Chokry
- Ons Ben Hadj Hassen
- Isis Blanchard
Institutions
- Centre National de la Recherche Scientifique (FR)
- Normandie Université (FR)
- Cyceron (FR)
- Université de Caen Normandie (FR)
Publication Details
- Journal
- Cancer Cell International
- Published
- 2026-05-02
- DOI
- https://doi.org/10.1186/s12935-026-04309-z
- Primary Topic
- Peroxisome Proliferator-Activated Receptors
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Ligue Contre le Cancer